124 related articles for article (PubMed ID: 38678826)
1. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
[TBL] [Abstract][Full Text] [Related]
2. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
[TBL] [Abstract][Full Text] [Related]
6. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo.
Guo J; Luo L; Wang Z; Hu N; Wang W; Xie F; Liang E; Yan X; Xiao J; Li S
J Med Chem; 2020 Nov; 63(22):13825-13850. PubMed ID: 33186040
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Cao H; Cheng B; Liu T; Chen J
Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway.
Zeng QX; Wang K; Zhang X; Shi YL; Dou YY; Guo ZH; Zhang XT; Zhang N; Deng HB; Li YH; Song DQ
Bioorg Chem; 2021 Dec; 117():105432. PubMed ID: 34678602
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
Song Z; Liu B; Peng X; Gu W; Sun Y; Xing L; Xu Y; Geng M; Ai J; Zhang A
J Med Chem; 2021 Nov; 64(22):16687-16702. PubMed ID: 34761679
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Qin M; Meng Y; Yang H; Liu L; Zhang H; Wang S; Liu C; Wu X; Wu D; Tian Y; Hou Y; Zhao Y; Liu Y; Xu C; Wang L
J Med Chem; 2021 May; 64(9):5519-5534. PubMed ID: 33938739
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction.
Fang L; Tian J; Zhang K; Zhang X; Liu Y; Cheng Z; Zhou J; Zhang H
Bioorg Med Chem; 2021 Sep; 46():116370. PubMed ID: 34481337
[TBL] [Abstract][Full Text] [Related]
20. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]